Hypertension Research
Online ISSN : 1348-4214
Print ISSN : 0916-9636
ISSN-L : 0916-9636
Comparison of the Antihypertensive Effects of the New Angiotensin II (AT1) Receptor Antagonist Candesartan Cilexetil (TCV-116) and the Angiotensin Converting Enzyme Inhibitor Enalapril in Rats
Takeo WadaYoshiyuki InadaMami OjimaTsukasa SanadaYumiko ShiboutaKohei Nishikawa
Author information
JOURNAL FREE ACCESS

1996 Volume 19 Issue 2 Pages 75-81

Details
Abstract
Antihypertensive effects of an angiotensin (Ang) II receptor antagonist, candesartan cilexetil (TCV-116), were compared with those of an angiotensin converting enzyme (ACE) inhibitor, enalapril, in spontaneously hypertensive rats (SHR), 2-kidney, 1-clip hypertensive rats (2K, 1C-HR) and 1-kidney, 1-clip hypertensive rats (1K, 1C-HR). CV-11974, the active form of TCV-116, had no inhibitory activity for plasma ACE. In rats, TCV-116 inhibited the pressor responses to Ang I, Ang II, and Ang III without an effect on the bradykinin (BK)-induced depressor response. Enalapril inhibited only the Ang I-response and potentiated the BK-response. In SHR, the antihypertensive effect of TCV-116 (10mg/kg) was larger than the maximum antihypertensive effect of enalapril and was not intensified by combination with enalapril. Administration of CV-11974 potentiated the maximum antihypertensive effect of enalapril. Although both agents reduced blood pressure in 2K, 1C-HR, only TCV-116 had a marked antihypertensive effect in 1K, 1C-HR. These findings indicate that TCV-116 is more effective than enalapril in reducing blood pressure in SHR and 1K, 1C-HR, and that the BK- and/or prostaglandin-potentiating effect of enalapril contributes little to its antihypertensive mechanism in SHR. (Hypertens Res 1996; 19: 75-81)
Content from these authors
© The Japanese Society of Hypertension
Previous article Next article
feedback
Top